柳叶刀,新英格兰医学杂志,大脑血管病 z-bio 2024-12-03 812

　　Previously, we shared tweets about negative results published in top medical journals, two of which were from the same research team. I don't know without checking, so this team is so awesome!
      They are the cerebrovascular disease center team composed of Professor Liu Jianmin, Professor Yang Pengfei, Professor Zhang Yongwei, and others from the First Affiliated Hospital of Naval Medical University (Changhai Hospital).

　　Stroke, commonly known as "stroke", is the first cause of death and disability for adults in China, with a high incidence rate, high disability rate, high mortality and high recurrence rate. In recent years, mechanical thrombectomy has rapidly developed as a minimally invasive treatment method that restores blood flow by directly removing thrombi from cerebral blood vessels, significantly improving patient prognosis.

　　The team led by Professor Liu Jianmin at the Cerebrovascular Disease Center is one of the earliest international teams to focus on the study of mechanical thrombectomy in stroke patients.

　　From Made in China to Intelligent Manufacturing in China

　　On May 7, 2020, the original work of the large-scale, prospective, multicenter, randomized controlled, clinical research project "Direct-MT Evaluation of the Efficacy of Direct Arterial Therapy for Acute Large Vessel Occlusive Ischemic Stroke in China" led by Professor Liu Jianmin's team was published online in the top medical journal "New England Journal of Medicine" (IF=96.2).

　　This is the first high-quality RCT study on intravascular treatment of acute ischemic stroke independently completed by Chinese people, and a high-quality research talent team, core laboratory platform, and clinical evaluation committee belonging to Chinese people have been established, realizing a breakthrough from "Made in China" to "Made in China".

　　The first confirmation of the safe lower limit of postoperative blood pressure management opens up a new era in stroke treatment!

　　Brave to reach new heights in evidence-based medicine

　　In November of this year, the results of two large-scale randomized controlled trials led by Professor Liu Jianmin's team - PROTECT-MT and MAGIC-MT - were simultaneously published in two top international medical journals, The Lancet and The New England Journal of Medicine, refreshing the new image of the field of neurointervention in China and even globally with their "hard power".

　　Professor Liu Jianmin once stated that the improvement of clinical treatment level relies on excellent clinical research, but for a considerable period of time, we lacked original, leading, and evidence-based high-quality clinical research, which once restricted the development of clinical treatment and made us have no voice internationally.
      In recent years, the team has caught up and continuously contributed Chinese original "answers" in the field of cerebrovascular intervention therapy. This unremitting effort and pursuit of excellence will undoubtedly inspire more researchers to devote themselves to this important field and make greater contributions to the cause of human health together.